Skip to main content

Brennan Daniel J.'s Form 4 filing

Boston Scientific Corp (BSX) · filed Feb 16, 2023

Accession no.
0001225208-23-002148
Filed
Feb 16, 2023
Trade date
Feb 15, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $356.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brennan Daniel J.CIK 0001595612Officer (EVP and CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2023Common StockMOption exerciseAcquired+7,572$7.39+$55,957.08280,954Direct
Feb 15, 2023Common StockMOption exerciseAcquired+4,153$0.00F2$0285,107Direct
Feb 15, 2023Common StockFTax withholdingDisposed−1,219$47.29−$57,646.51283,888Direct
Feb 15, 2023Common StockSSaleDisposed−7,572$47.14F3−$356,944.08276,316Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2023Common StockMOption exerciseDisposed−4,153$0.00$00Direct
Feb 15, 2023Common StockMOption exerciseDisposed−7,572$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.993 to $47.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)